RxDoctor Payments Data

Roggie Reason, MD

Internal Medicine · Minot, NDNPI 1366797045

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 17 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by Astellas Pharma US Inc at 31.6% of the total.

$276in general payments, 2019–2025

Across 17 payments — averaging $16.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$87
  • Amgen$86
  • Itamar Medical Inc$25
  • Bayer$21
  • Johnson & Johnson$18
  • Lilly USA, LLC$16
  • plus $23 from 2 others

What the payments were for

  • Food & beverage$276100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$276 in reported general payments places this provider in the 60th percentile of 159 internal medicine providers in North Dakota.

See all internal medicine providers in North Dakota

Medicare billing

Part B allowed, 2024
$175,847
Medicare patients
833
Services billed
1,977

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban391$394,653
OzempicSemaglutide320$375,498
MounjaroTirzepatide249$276,671
JardianceEmpagliflozin157$151,038
XareltoRivaroxaban139$130,912
Fiasp FlextouchInsulin Aspart (Niacinamide)71$51,934
Tresiba Flextouch U-100Insulin Degludec98$49,766
Trelegy ElliptaFluticasone/Umeclidin/Vilanter56$48,156
TrulicityDulaglutide53$48,129
Tresiba Flextouch U-200Insulin Degludec50$35,522
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr51$28,833
JanuviaSitagliptin Phosphate21$27,624
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog47$26,711
MyrbetriqMirabegron21$23,636
Breo ElliptaFluticasone/Vilanterol30$20,204

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Abrysvo$11$406,935435 claims
Lilly USA, LLCMounjaro, Trulicity$16$324,800302 claims
Johnson & JohnsonXarelto$18$130,912139 claims
Astellas Pharma US IncMyrbetriq$87$23,63621 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 159 internal medicine providers in North Dakota.

Other internal medicine in Minot

See the full list for North Dakota

Where these figures come from

Is this you, or does something look wrong? →